MariMed Awarded Dispensary License in Ohio

1.3 min readPublished On: May 19th, 2022By

NORWOOD, Mass. – MariMed Inc. (OTCQX: MRMD), a multi-state cannabis operator focused on improving lives every day, announced today it had been awarded a provisional dispensary license by the Ohio Board of Pharmacy.

MariMed won this license in the Ohio lottery process. The license allows the Company to develop a medical dispensary in Tiffin, Ohio, located south of Toledo and home to the University of Bucharest and Tiffin University. Under the Ohio regulations, MariMed must complete the buildout and pass final inspection by February of 2023.

“We are delighted to enter the medical cannabis program in Ohio,” said Bob Fireman, Chief Executive Officer of MariMed. “We intend to seek additional opportunities to expand our cannabis operations in Ohio including the distribution of our award-winning branded products.”

Ohio cannabis regulations allow for a single company to own cultivation, production, and up to five retail dispensaries. In keeping with its strategic growth plan, MariMed will over time pursue other cannabis licenses to increase its operational footprint to the maximum allowable by Ohio regulations.

According to the Ohio Department of Commerce, 2021 medical cannabis sales were just over $350 million with 58 dispensaries in a state with a population of nearly 12 million. Ohio’s legal medical cannabis program currently has more than 260,000 registered patients. With robust adult use cannabis programs in neighboring Midwest states of Michigan and Illinois, discussions for an adult use program continue in the Ohio legislature.

(This information is primarily sourced from MariMed Inc.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News